1. Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 2. Institute of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen, China. 4. Department of Geriatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 5. Institute of Gerontology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 6. Department of Pathogenic Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China. 7. Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. †These authors have contributed equally to this work
Wang Q, Gao S, Shou Y, Jia Y, Wei Z, Liu Y, Shi J, Miao D, Miao Q, Zhao C, Liu C, Yang H, Xu T, Zhang X. AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis. Int J Biol Sci 2023; 19(4):1266-1283. doi:10.7150/ijbs.79853. https://www.ijbs.com/v19p1266.htm
Renal cell carcinoma (RCC) is a serious threat to people's health due to its rapid progression, and patients easily develop resistance to targeted therapy. The absent in melanoma 2 (AIM2) is a receptor protein that has recently been proposed to play an important role in various diseases. In this study, AIM2 was identified as a new biomarker of RCC and promoted RCC progression and sunitinib resistance in an inflammasome-independent manner. Mechanistically, AIM2 promoted FOXO3a phosphorylation and proteasome degradation, thereby reducing its transcriptional effect on ACSL4 and inhibiting ferroptosis. In summary, AIM2 promoted RCC progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis, which could provide new ideas and therapeutic targets for RCC diagnosis and treatment.
Wang Q, Gao S, Shou Y, Jia Y, Wei Z, Liu Y, Shi J, Miao D, Miao Q, Zhao C, Liu C, Yang H, Xu T, Zhang X. AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis. Int J Biol Sci 2023; 19(4):1266-1283. doi:10.7150/ijbs.79853. https://www.ijbs.com/v19p1266.htm
CSE
Wang Q, Gao S, Shou Y, Jia Y, Wei Z, Liu Y, Shi J, Miao D, Miao Q, Zhao C, Liu C, Yang H, Xu T, Zhang X. 2023. AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis. Int J Biol Sci. 19(4):1266-1283.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.